BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 31, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Velcade bortezomib: Final Phase I/II data

Final data from a Phase I/II trial in 66 previously untreated MM patients showed that Velcade plus Revlimid lenalidomide and dexamethasone produced at least a partial response in all patients. Specifically, 39% of patients achieved a near complete or complete response and 67% of patients achieved at least...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >